Stockmarkets Bristol Myers Squibb and Cellares reach $380 million supply deal for CAR-T therapies Read more
Biotechnology FDA Mandates “Boxed Warning” For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies – Johnson & Johnson (NYSE:JNJ), Novartis (NYSE:NVS), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY) Read more
Biotechnology Why Is Intra-Cellular Stock Trading Higher Today? – Intra-Cellular Therapies (NASDAQ:ITCI) Read more
Biotechnology Spinal Delivery Of Taysha’s Gene Therapy Shows Promise In Rare Childhood Neurodegenerative Disease – Taysha Gene Therapies (NASDAQ:TSHA) Read more
Biotechnology Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana’s Research And More – ATAI Life Sciences (NASDAQ:ATAI), Clearmind Medicine (NASDAQ:CMND) Read more
Biotechnology Taysha Gene Therapies Stock Soars On FY23 Results: Here’s Why – Taysha Gene Therapies (NASDAQ:TSHA) Read more
Biotechnology Taysha Gene Therapies Shares Jump On Initial Data From First Pediatric Patient With Rare Neurodevelopmental Disorder – Taysha Gene Therapies (NASDAQ:TSHA) Read more
Biotechnology FDA To Review Two Cell Therapies For Multiple Myeloma This Week – Johnson & Johnson And Bristol-Myers – Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb (NYSE:BMY) Read more
Biotechnology Arcellx’s Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson’s Multiple Myeloma Cell Therapies: Morgan Stanley – Arcellx (NASDAQ:ACLX) Read more